TRVN Trevena

Trevena to Participate in Upcoming Conferences in September 2019

Trevena to Participate in Upcoming Conferences in September 2019

CHESTERBROOK, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will participate in two upcoming conferences:

  • H.C. Wainwright 21st Annual Global Investment Conference, sponsored by H.C. Wainwright, to be held at the Lotte New York Palace Hotel in New York City on Tuesday, September 10, 2019 at 9:35am ET. 



    Live audio webcast and archived replay of the presentation will be available on Trevena’s investor relations website at . Following the conclusion of the presentation, the webcast will be available for replay for 30 days. 



  • Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, sponsored by Oppenheimer & Co., to be held at the  Parker New York Hotel in New York City on Wednesday, September 23 and Thursday, September 24, 2019.

For more information about the conferences, or to schedule a one-on-one meeting with Trevena’s management, please contact KCSA Strategic Communications at , or send an email to (H.C. Wainright), or (Oppenheimer & Co.).

About Trevena

Trevena, Inc.  is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions.  The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.

For more information, please contact:

Investor Contact:

Valter Pinto / Allison Soss

KCSA Strategic Communications

Phone: 212-896-1254 / 212-896-1267

Email:  

Company Contact:

Bob Yoder, SVP and Chief Business Officer

Trevena, Inc.

Phone: 610-354-8840

EN
03/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trevena

 PRESS RELEASE

Trevena Reports Third Quarter 2024 Results and Provides Business Updat...

Trevena Reports Third Quarter 2024 Results and Provides Business Update CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a ...

 PRESS RELEASE

Trevena Announces Receipt of Nasdaq Delisting Notification

Trevena Announces Receipt of Nasdaq Delisting Notification CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common stock from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with the minimum stockholder’s equity requirement u...

 PRESS RELEASE

Trevena Announces Reverse Stock Split

Trevena Announces Reverse Stock Split CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena’s common stock will continue ...

 PRESS RELEASE

Trevena Reports Second Quarter 2024 Results and Provides Business Upda...

Trevena Reports Second Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in preclinical models $12 million financing completed, including non-dilutive $2 million tranche and $10 million reduction in liabilities associated with existing ex-US royalty financing CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused o...

 PRESS RELEASE

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in ...

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing CHESTERBROOK, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch